Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs

American Journal of the Medical Sciences

Volumn 340, Issue 4, 2010, Pages 282-290

  Contreras Yáñez, Irazú ^a   Ponce De León, Sergio ^a   Cabiedes, Javier ^a   Rull Gabayet, Marina ^a   Pascual Ramos, Virginia ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Compliance; Disease Flares; Rheumatoid arthritis

Indexed keywords

CHLOROQUINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; MONOTHERAPY; PATIENT COMPLIANCE; PROGNOSIS; QUESTIONNAIRE; REMISSION; RHEUMATOID ARTHRITIS;

EID: 77957985245     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181e8bcb0     Document Type: Article

References (40)

1. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-494
2. National Committee for Quality Assurance. HEDIS 2006 technical specifications: disease modifying anti-rheumatic drug therapy in rheumatoid arthritis. Washington (DC): National Committee for Quality Assurance; 2005.
3. Kahn KL, Mclean CH, Wong AL, et al. Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort. Arthritis Rheum 2007;57: 707-715
4. Zink A, Listing J, Kary S, Ramlau P, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-1279
5. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497
6. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence terminology and definitions. Value Health 2008;11:44-47
7. DiMatteo MR, Giordani PJ, Lepper H, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002;40:794-811.
8. Cramer JA. Partial medication compliance: the enigma in poor medical outcomes. Am J Manag Care 1995;1:45-52.
9. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 2009;38:396-402.
10. de Klerk E, van der Heijde D, Landewé R, et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54.
11. Gossec L, Tubach F, Dougados M, et al. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. Am J Med Sci 2007;334:248-254
12. Deyo RA, Inui TS, Sullivan B. Noncompliance with arthritis drugs: magnitude, correlates, and clinical implications. J Rheumatol 1981;8: 931-936
13. Tuncay R, Eksioglu E, Cakir B, et al. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int 2007; 27:743-746
14. García-González A, Richardson M, García Popa-Lisseanu M, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2008;27:883-889
15. Lorish CD, Richards B, Brown S. Missed medication doses in rheumatic arthritis patients: intentional and unintentional reasons. Arthritis Care Res 1989;2:3-9.
16. Lorish CD, Richards B, Brown S. Perspective of the patient with rheumatoid arthritis on issues related to missed medication. Arthritis Care Res 1990;3:78-84.
17. Viller F, Guillemin F, Briançon S, et al. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 1999;26:2114-2122
18. Viller F, Guillemin F, Briançon S, et al. Compliance with drug therapy in rheumatoid arthritis. A longitudinal European study. Joint Bone Spine 2000;67:178-182
19. Grijalva CG, Chung CP, Arbogast PG, et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007; 45(suppl 2):S66 -76.
20. Curkendall S, Patel V, Gleeson M, et al. Compliance with biologic therapies for rheumatoid arthritis: do patients out-of-pocket payments matter? Arthritis Care Res 2008;59:1519-1526
21. Pascual-Ramos V, Contreras-Yáñez I, Villa AR, et al. Medication persistence over two years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and disability. Arthritis Res Ther 2009;11:R26.
22. Walsh JC, Mandalia S, Gazzard BG. Responses to a month selfreport on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002;16:269-277
23. Haynes RB, Taylor DW, Sackett DL, et al. Can simple clinical measurements detect patient noncompliance? Hypertension 1980;2: 757-764
24. Cramer J, Rosenheck R, Kirk G, et al. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6:566-573
25. Callahan LF, Brooks RH, Pincus T. Further analysis of learned helplessness in rheumatoid arthritis using a "Rheumatology Attitudes Index." J Rheumatol 1988;15:418-426
26. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992; status and review. Arthritis Care Res 1992;5:119-129
27. Prevoo ML, van-t Hof MA, Kuper HH, et al. Modified disease activity score that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
28. Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis. Arthritis Rheum 2005;52:2625-2636
29. Rosner B. Fundamentals of biostatistics, 5th ed. Boston (MA): Duxbury Press; 2000.
30. Matthews JNS, Altman DG, Campbell MJ, et al. Analysis of serial measurement in medical research. Br Med J 1990;300:230-235
31. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2006;10:3-12.
32. Lee P, Tan LJ. Drug compliance in outpatients with rheumatoid arthritis. Aust N Z J Med 1979;9:274-277
33. Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in Southern Sweden. Arthritis Res Ther 2006;8:R174.
34. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-1602
35. Dougados M, Emery P, Lemmel EM, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6 months data. J Rheumatol 2003;30:2572-2579
36. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-733
37. de Klerk E, van der Heijde D, van der Tempel H. Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol 1999;26:2635-2641
38. de Klerk E, van der Heijde D, van der Tempel H, et al. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol 2003;30: 2469-2475
39. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600-606
40. Bannwarth B, Pehourcq F, Schaeverbeke T, et al. Clinical pharmacokinetics of low dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30:194-210.